Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Core Insights - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases and aims to present significant progress at the upcoming NobleCon21 conference [1][2][4] - The company is targeting three Biologics License Applications (BLAs) within three years and plans to discuss near-term catalysts for 2026 during the conference [2][4] Company Overview - Ocugen's modifier gene therapy platform addresses complex diseases caused by imbalances in multiple gene networks, offering a gene-agnostic approach [4] - Current development programs include treatments for inherited retinal diseases and blindness diseases such as retinitis pigmentosa, Stargardt disease, and geographic atrophy [4] Conference Details - Dr. Shankar Musunuri will present on December 3, 2025, at 1 p.m. ET, with a focus on the company's scientific platform and clinical development strategy [2] - A high-definition video webcast of the presentation will be available the following day and archived for 90 days [3]